Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States | Zendy

Mohammad Jahanzeb | Zendy; Huamao Mark Lin | Zendy; Yanyu Wu | Zendy; Pingkuan Zhang | Zendy; Magdaliz Gorritz | Zendy; Catherine B. McGuiness | Zendy; WeiTi Huang | Zendy; Kainan Sun | Zendy; ChiChang Chen | Zendy; D. Ross Camidge | Zendy

Open Access

Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States

Author(s) -

Mohammad Jahanzeb,

Huamao Mark Lin,

Yanyu Wu,

Pingkuan Zhang,

Magdaliz Gorritz,

Catherine B. McGuiness,

WeiTi Huang,

Kainan Sun,

ChiChang Chen,

D. Ross Camidge

Publication year - 2022

Publication title -

the oncologist

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.176

H-Index - 164

eISSN - 1549-490X

pISSN - 1083-7159

DOI - 10.1093/oncolo/oyac116

Subject(s) - crizotinib , alectinib , medicine , discontinuation , tolerability , anaplastic lymphoma kinase , ceritinib , lung cancer , oncology , adverse effect , malignant pleural effusion

Real-world evidence for brigatinib, a next-generation anaplastic lymphoma kinase-tyrosine kinase inhibitor (ALK-TKI) used in ALK-rearranged non-small cell lung cancer, is scarce. This retrospective study evaluated real-world brigatinib utilization in the US post other ALK-TKIs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research